[go: up one dir, main page]

MA46952A - Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet - Google Patents

Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet

Info

Publication number
MA46952A
MA46952A MA046952A MA46952A MA46952A MA 46952 A MA46952 A MA 46952A MA 046952 A MA046952 A MA 046952A MA 46952 A MA46952 A MA 46952A MA 46952 A MA46952 A MA 46952A
Authority
MA
Morocco
Prior art keywords
immuno
antibodies
radio
pet imaging
marked anti
Prior art date
Application number
MA046952A
Other languages
English (en)
Inventor
Marcus Kelly
Dangshe Ma
William Olson
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA46952A publication Critical patent/MA46952A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA046952A 2016-12-01 2017-12-01 Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet MA46952A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428672P 2016-12-01 2016-12-01
US201762457267P 2017-02-10 2017-02-10
US201762569773P 2017-10-09 2017-10-09

Publications (1)

Publication Number Publication Date
MA46952A true MA46952A (fr) 2019-10-09

Family

ID=60766172

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046952A MA46952A (fr) 2016-12-01 2017-12-01 Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet

Country Status (17)

Country Link
US (4) US10736976B2 (fr)
EP (2) EP4649966A3 (fr)
JP (1) JP7105235B2 (fr)
KR (1) KR102611270B1 (fr)
CN (1) CN110234661B (fr)
AU (1) AU2017367734B2 (fr)
BR (1) BR112019011186A2 (fr)
CA (1) CA3045466A1 (fr)
CL (1) CL2019001483A1 (fr)
CO (1) CO2019005842A2 (fr)
IL (2) IL266885B1 (fr)
MA (1) MA46952A (fr)
MX (1) MX389083B (fr)
MY (1) MY191926A (fr)
PH (1) PH12019501146A1 (fr)
PT (1) PT3548515T (fr)
WO (1) WO2018102682A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
SG10201913297TA (en) 2015-03-13 2020-02-27 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
MA44146B1 (fr) 2015-12-22 2023-10-31 Regeneron Pharma Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
MA46952A (fr) * 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
IL313695A (en) * 2017-02-10 2024-08-01 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN117442719A (zh) 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
USD825184S1 (en) 2017-02-22 2018-08-14 Yeti Coolers, Llc Bag
US11076666B2 (en) 2017-03-08 2021-08-03 Yeti Coolers, Llc Container with magnetic closure
EP4424206A3 (fr) 2017-03-08 2024-11-27 YETI Coolers, LLC Récipient à fermeture magnétique
US10954055B2 (en) 2017-03-08 2021-03-23 Yeti Coolers, Llc Container with magnetic closure
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
WO2019227490A1 (fr) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions et procédés d'imagerie
US11987629B2 (en) 2018-06-01 2024-05-21 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
EP3826673A4 (fr) * 2018-07-26 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions et procédés d'imagerie
US12263234B2 (en) 2019-01-23 2025-04-01 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-PD-L1 diabodies and the use thereof
USD909063S1 (en) 2019-03-08 2021-02-02 Yeti Coolers, Llc Bag
SG11202111262XA (en) 2019-05-13 2021-11-29 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2022046833A1 (fr) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1
CN114316045B (zh) * 2020-09-29 2024-07-12 英诺欧奇生物医药(苏州)有限公司 抗pd-l1抗体及其用途
US11992104B2 (en) 2022-02-16 2024-05-28 Yeti Coolers, Llc Container with resealable closure
KR20250099774A (ko) 2022-10-03 2025-07-02 리제너론 파아마슈티컬스, 인크. 이중특이적 egfr x cd28 항체를 단독으로 또는 항-pd-1 항체와 조합하여 사용하여 암을 치료하는 방법
WO2024192033A1 (fr) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de pd-1 et d'inhibiteurs de lag-3 pour une efficacité améliorée dans le traitement d'un mélanome
AU2024287529A1 (en) 2023-07-10 2026-02-05 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1x4-1bb antibodies and methods of use thereof
WO2025106736A2 (fr) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de pd-1 et d'inhibiteurs de lag-3 pour une efficacité améliorée dans le traitement du cancer du poumon

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
AU628988B2 (en) 1989-05-04 1992-09-24 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors and complexes therefor
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US5939535A (en) 1995-10-27 1999-08-17 The Board Of Regents Of The University Of Nebraska Acetaldehyde and malondialdehyde protein adducts
BR9712410A (pt) 1996-10-18 1999-10-19 Genentech Inc Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
AU6542898A (en) 1997-03-05 1998-09-22 John Wayne Cancer Institute Sialyl lewis antigens as targets for immunotherapy
US6913756B1 (en) 1998-04-29 2005-07-05 The Uab Research Foundation Monoclonal antibodies specific for anthrax and peptides derived from the antibodies thereof
PT1086223E (pt) 1998-06-01 2009-11-03 Agensys Inc Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US6787638B1 (en) 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030139327A9 (en) 2000-01-31 2003-07-24 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU2001249727A1 (en) 2000-03-31 2001-10-15 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
EP1578371A4 (fr) 2002-08-19 2009-05-20 Genentech Inc Compositions et methodes de diagnostic et de traitement des tumeurs
AU2002338020A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
JP4884224B2 (ja) 2003-05-09 2012-02-29 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
WO2005000894A2 (fr) 2003-06-25 2005-01-06 Crucell Holland B.V. Molecules de liaison pour traiter les malignites de cellules myeloides
DE10339820A1 (de) 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs
SI2311873T1 (sl) 2004-01-07 2018-12-31 Novartis Vaccines And Diagnostics, Inc. M-CSF-specifična monoklonska protitelesa in njihova uporaba
SI1742966T1 (sl) 2004-04-22 2014-03-31 Agensys, Inc. Protitelesa in iz njih izvedene molekule, ki se veĹľejo na STEAP-1 proteine
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US20080193376A1 (en) 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
WO2006050058A2 (fr) 2004-10-28 2006-05-11 The General Hospital Corporation Methodes de detection et de therapie de tissus enflammes par immunomodulation
ES2402277T3 (es) 2004-11-10 2013-04-30 Diadexus, Inc. Composiciones de anticuerpo contra Ovr110 y procedimientos de uso
CA2600505C (fr) 2005-03-10 2016-05-03 Morphotek, Inc. Anticorps diriges contre la mesotheline
EP3058955B1 (fr) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Anticorps se liant à l'ov064 et leurs procédés d'utilisation
KR20080009682A (ko) 2005-04-01 2008-01-29 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 킬레이트제인 폴리(펩티드): 제조 방법과 용도
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7718369B2 (en) 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US7901665B2 (en) 2005-11-30 2011-03-08 General Electric Company Conjugated macromolecules
WO2007109347A2 (fr) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadhérine et ly6 e: cibles pour diagnostic et traitement du cancer
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
EP2078732B1 (fr) 2006-07-10 2015-09-16 Fujita Health University Procédé pour l'identification des anticorps diagnostic ou thérapeutiques par cytométrie en flux
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
WO2008067283A2 (fr) 2006-11-27 2008-06-05 Diadexus, Inc. Compositions d'anticorps ovr110 et leurs procédés d'utilisation
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
WO2008124467A1 (fr) 2007-04-06 2008-10-16 Macrocyclics Ligands d'acide hydroxamique bifonctionnels et procede de synthese associe
EP2144628B1 (fr) 2007-05-08 2012-10-17 Genentech, Inc. Anticorps anti-muc16 produits avec de la cystéine et conjugués anticorps-médicament
DK2173379T3 (en) 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
CN101855554B (zh) 2007-09-07 2014-05-14 儿童医院医学中心 分泌者、Lewis和唾液酸化抗原水平作为疾病预测指标的用途
EP2584043A3 (fr) 2007-09-28 2013-10-02 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée
CA2700860C (fr) 2007-10-01 2016-07-19 Jonathan A. Terrett Anticorps humains qui se lient a la mesotheline, et utilisations de ceux-ci
WO2009051974A1 (fr) 2007-10-17 2009-04-23 Nuvelo, Inc. Anticorps anti-cll-1
EP2216344B1 (fr) 2007-11-14 2017-06-28 Chugai Seiyaku Kabushiki Kaisha Diagnostic et traitement du cancer à l'aide d'un anticorps anti-gpr49
NZ585551A (en) 2007-11-26 2012-06-29 Bayer Schering Pharma Ag Anti-mesothelin antibodies and uses therefor
MX2010005830A (es) 2007-11-30 2010-09-14 Bristol Myers Squibb Co Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
ES2547552T3 (es) 2008-02-01 2015-10-07 Genentech, Inc. Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
CA2718321A1 (fr) 2008-03-27 2009-10-01 Dimiter S. Dimitrov Anticorps monoclonaux anti-mesotheline humaine
US9381262B2 (en) 2008-04-24 2016-07-05 The Australian National University Methods for radiolabeling synthetic polymers
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
WO2010016766A2 (fr) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène
JP5778577B2 (ja) 2008-09-19 2015-09-16 メディミューン，エルエルシー Ｄｌｌ４に対する抗体およびその使用
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
WO2010091637A1 (fr) 2009-02-10 2010-08-19 Shenogen Pharma Group Ltd. Anticorps et méthodes de traitement de maladies associées à un récepteur d'œstrogène
CA2756393C (fr) 2009-03-24 2017-06-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anticorps anti-mesotheline
US20100279301A1 (en) 2009-05-04 2010-11-04 The Regents Of The University Of Michigan Methods and compositions for diagnosing bladder cancer
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
RU2598711C2 (ru) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
CA2824719C (fr) 2011-01-19 2020-06-02 Cantargia Ab Anticorps anti-il1rap et leur utilisation dans le traitement de tumeurs solides
EP2681243B1 (fr) 2011-03-03 2018-09-05 Apexigen, Inc. Anticorps anti-récepteurs il-6 et leurs procédés d'utilisation
WO2012158960A2 (fr) 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Ligands du récepteur à la mélanocortine de type 1 et leurs procédés d'utilisation
WO2013010573A1 (fr) 2011-07-18 2013-01-24 Universitaet Muenster Composés avec activité inhibitrice de métalloprotéinase de matrice
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
JP2014525904A (ja) 2011-06-28 2014-10-02 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ タンパク質連結用クリックケミストリーハンドルを設置するためのソルターゼの使用
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
AU2012298794A1 (en) 2011-08-23 2013-04-04 Infinity Pharmaceuticals, Inc. Biomarkers predictive of therapeutic responsiveness to HSP90 inhibitors and uses thereof
US20140308204A1 (en) 2011-10-25 2014-10-16 Memorial Sloan Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
PL2771037T3 (pl) 2011-10-28 2017-06-30 Fredax Ab Środki terapeutyczne i ich zastosowania
WO2013070468A1 (fr) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Anticorps spécifique de glypican-3 et ses utilisations
CA2855356A1 (fr) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilite a des inhibiteurs du proteasome
JP6120416B2 (ja) 2012-01-06 2017-04-26 リンクシス ビー．ヴイ． 細胞標的コンジュゲートを調製するための方法、及び得られる錯体
WO2013138696A1 (fr) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Complexes de zirconium-89, procédés de marquage de cellules, cellules marquées, kits et leurs procédés d'utilisation
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
CA2870485A1 (fr) 2012-04-13 2013-10-17 Whitehead Institute For Biomedical Research Domaines vhh modifies par sortase et applications associees
WO2013158841A1 (fr) 2012-04-18 2013-10-24 The Regents Of The University Of California Mimotopes peptidiques vis-à-vis d'épitopes spécifiques de l'oxydation
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2013177055A2 (fr) 2012-05-21 2013-11-28 Genentech, Inc. Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
DE102012104504B4 (de) 2012-05-24 2021-10-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Wirtschaft und Technologie, dieses vertreten durch den Präsidenten der BAM, Bundesanstalt für Materialforschung und -prüfung Polypeptidmarker
US20150191543A1 (en) 2012-08-06 2015-07-09 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
CN103736092A (zh) 2012-08-09 2014-04-23 清华大学 抑制新生淋巴管生成的方法和药物
CN104704359A (zh) 2012-10-25 2015-06-10 生命科技公司 糖蛋白酶介导位点特异性放射性标记的方法和组合物
EP2740726A1 (fr) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Ligands de récepteurs de la neurotensine
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2014133093A1 (fr) * 2013-02-28 2014-09-04 独立行政法人国立がん研究センター Anticorps dirigé contre la fibrine insoluble
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
CA2904969C (fr) 2013-03-13 2025-06-17 Imaginab, Inc. Constructions génétiques de liaison à l'antigène de cluster de différenciation 8
CN105189552B (zh) 2013-03-14 2019-08-02 基因泰克公司 抗b7-h4抗体和免疫缀合物
US20160000946A1 (en) 2013-03-14 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US9511350B2 (en) 2013-05-10 2016-12-06 Clean Diesel Technologies, Inc. (Cdti) ZPGM Diesel Oxidation Catalysts and methods of making and using same
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014200969A2 (fr) 2013-06-10 2014-12-18 Millennium Pharmaceuticals, Inc. Méthodes de traitement du cancer
DE102013106066A1 (de) 2013-06-11 2014-12-11 Johannes-Gutenberg-Universität Mainz Bifunktionelle Chelatbildner auf der Basis des 1,4-Diazepin-Gerüsts (DAZA) für die nicht invasive molekulare Bilddarstellung
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
SG11201603125SA (en) 2013-10-21 2016-05-30 Genentech Inc ANTI-Ly6E ANTIBODIES AND METHODS OF USE
WO2015073746A2 (fr) 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research Marquage de protéines au 18f, faisant appel à des sortases
AU2014351611B2 (en) 2013-11-19 2020-04-23 Janssen Biotech, Inc. Humanised anti kallikrein-2 antibody
PE20160712A1 (es) 2013-12-13 2016-07-26 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
PT3131585T (pt) 2014-03-19 2020-10-23 Univ Zuerich Agentes quelantes bifuncionais multidentados para complexação de radionuclídeos em diagnóstico e terapia
KR20170003582A (ko) 2014-05-22 2017-01-09 제넨테크, 인크. 항-gpc3 항체 및 면역접합체
WO2015188934A1 (fr) 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugué comprenant un ligand de récepteur de neurotensine et son utilisation
CA2949982A1 (fr) 2014-06-11 2015-12-17 Genentech, Inc. Anticorps anti-lgr5 et leurs utilisations
BR112016029650A2 (pt) * 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
JP6945444B2 (ja) * 2014-08-08 2021-10-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｐｄ−１薬剤とその使用方法
MX2017003126A (es) 2014-09-12 2017-08-28 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados.
SG11201701627PA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
CN113698485A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
ES2745848T3 (es) 2014-10-16 2020-03-03 Univ Melbourne Composición novedosa de diagnóstico por imágenes y usos de la misma
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
CA2969067A1 (fr) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Nouveaux polypeptides fixant pd-l1 pour l'imagerie
CA2968675C (fr) 2014-12-09 2023-10-17 Regeneron Pharmaceuticals, Inc. Animaux non-humains presentant un groupe de gene groupe de differenciation 274 humanise
US11534506B2 (en) 2015-03-06 2022-12-27 Mayo Foundation For Medical Education And Research Methods for cell labeling and medical imaging
NL2014423B1 (en) 2015-03-09 2016-10-13 Linxis B V Method for removing weakly bound functional moieties from cell targeting conjugates.
WO2016162368A1 (fr) * 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Imagerie non invasive de l'expression de pd-l1 d'une tumeur
ES2802234T3 (es) 2015-05-22 2021-01-18 Memorial Sloan Kettering Cancer Center Sistemas y métodos para determinar la dosis óptima y específica para el paciente de anticuerpos dirigidos al tumor
EP4218833A1 (fr) 2015-10-01 2023-08-02 Whitehead Institute for Biomedical Research Marquage d'anticorps
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
HRP20210644T8 (hr) 2016-05-19 2021-06-25 Bristol-Myers Squibb Company Imunomodulatori za pet-snimanje
EP3463578A1 (fr) 2016-06-06 2019-04-10 LinXis B.V. Conjugués de ciblage de cellules
US11179484B2 (en) 2016-06-24 2021-11-23 University Of Iowa Research Foundation Compositions and methods of treating melanoma
EP3266465A1 (fr) 2016-07-06 2018-01-10 Julius-Maximilians-Universität Würzburg Complexes immuns
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CA3031076C (fr) 2016-07-18 2023-10-03 Wisconsin Alumni Research Foundation Agents radiohalogenes pour vaccination contre le cancer immunomodulee in situ
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
EP3515495A4 (fr) 2016-09-26 2020-08-26 Ensemble Group Holdings Procédés d'évaluation et de traitement du cancer chez des sujets ayant des systèmes lymphatiques dysrégulés
WO2018128664A2 (fr) 2016-10-20 2018-07-12 The University Of North Carolina At Chapel Hill Composés marqués au 18f pour l'imagerie tep, et utilisations associées
US11266639B2 (en) 2016-11-07 2022-03-08 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet

Also Published As

Publication number Publication date
MX2019006448A (es) 2020-02-05
US20240335572A1 (en) 2024-10-10
CN110234661B (zh) 2024-03-29
US20200345872A1 (en) 2020-11-05
BR112019011186A2 (pt) 2019-10-08
MY191926A (en) 2022-07-18
EP3548515B1 (fr) 2026-01-21
KR102611270B1 (ko) 2023-12-08
EP4649966A2 (fr) 2025-11-19
PH12019501146A1 (en) 2019-08-19
CA3045466A1 (fr) 2018-06-07
IL266885B1 (en) 2025-12-01
US20180161464A1 (en) 2018-06-14
PT3548515T (pt) 2026-01-30
US10736976B2 (en) 2020-08-11
EP3548515A1 (fr) 2019-10-09
CO2019005842A2 (es) 2019-08-30
US12053534B2 (en) 2024-08-06
CN110234661A (zh) 2019-09-13
CL2019001483A1 (es) 2019-12-06
JP7105235B2 (ja) 2022-07-22
AU2017367734A1 (en) 2019-06-20
IL324632A (en) 2026-01-01
US20220184241A1 (en) 2022-06-16
AU2017367734B2 (en) 2025-01-09
IL266885A (en) 2019-07-31
JP2020512281A (ja) 2020-04-23
KR20190101975A (ko) 2019-09-02
WO2018102682A1 (fr) 2018-06-07
EP4649966A3 (fr) 2026-02-18
MX389083B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
FR24C1056I2 (fr) Nouveaux anticorps anti-pd-l1
FR25C1022I1 (fr) Anticorps anti-pd-1
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
MA52742A (fr) Anticorps bispécifiques dll3-cd3
HUE051700T2 (hu) Anti-PD-1 antitestek
DK3455257T3 (da) Anti-pd-l1-antistoffer
MA47456A (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
MA46057A (fr) Anticorps anti-ctla4
EP3334824A4 (fr) Anticorps anti-pd-1
EP3498840A4 (fr) Anticorps anti-lag-3
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
EP3423089A4 (fr) Anticorps anti-tigit
MA43028A (fr) Anticorps bispécifiques pour pd1 et tim3
EP3532489A4 (fr) Anticorps monoclonaux neutralisants anti-tl1a
EP3383915A4 (fr) Anticorps anti-pd-1
EP3307777A4 (fr) Nouveaux anticorps anti-pd-l1
EP3492591A4 (fr) Anticorps anti-b7-h4
PT3311171T (pt) Epítopo de anticorpos
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3399992A4 (fr) Anticorps autoréticulants
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
EP3746120A4 (fr) Anticorps anti-pd-1
EP3532034A4 (fr) Anticorps anti-apoe
PL3474904T3 (pl) Otrzymywanie przeciwciał monoklonalnych znakowanych 212pb